Secukinumab shows positive effects in HS at 52 weeks
Patients with moderate to severe hidradenitis suppurativa (HS) treated with secukinumab demonstrate sustained efficacy and symptom...
Secukinumab shows positive effects in HS at 52 weeks
Seamless 3D artificial skin shows promise
VIDEO: Researchers develop new non-invasive burn assessment method
Improved understanding of pathways could lead to new hair loss therapies
Bioprinted skin model accurately reacts to irritants
Upadacitinib effective for treating hand eczema in AD patients
Gene mutations could point to new treatments for scleroderma
Common comorbidities associated with abnormal scarring identified